Open AccessEconomic Evaluation of Drug Resistance Genotyping for the Adaptation of Treatment in HIV-Infected Patients in the VIRADAPT Study
Author(s) -
Carine Chaix,
Catherine GrenierSennelier,
Philippe Clevenbergh,
J. Durant,
Jonathan Schapiro,
P. Dellamonica,
Isabelle DurandZaleski
Publication year - 2000
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/00126334-200007010-00005
Subject(s) - medicine , reimbursement , genotyping , pharmacy , hiv drug resistance , activity based costing , cost database , emergency medicine , health care , economic evaluation , family medicine , intensive care medicine , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy , genotype , database , business , biochemistry , chemistry , pathology , marketing , computer science , economics , gene , economic growth
Costs of antiretroviral therapy for HIV-infected patients have increased at a time when most countries are attempting to contain health care costs. Part of this increase results from HIV drug resistance associated with virologic failure and a subsequent shift to more complex and costly therapies. Genotypic guided treatment is associated with better virologic outcome. However, it is not yet known whether it will be cost effective.